#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

A new perspective on axillary dissection in situations of metastatic sentinel node


Authors: I. Zedníková 1;  A. Ňaršanská 1;  O. Hes 2;  A. Metelková 3;  O. Fiala 3;  T. Svoboda 3
Authors‘ workplace: Chirurgická klinika FN Plzeň-Lochotín přednosta: prof. MUDr. V. Třeška, DrSc. 1;  Šiklův patologicko-anatomický ústav FN Plzeň přednosta: prof. MUDr. M. Michal 2;  Onkologická a radioterapeutická klinika FN Plzeň přednosta: prof. MUDr. J. Fínek, Ph. D. 3
Published in: Rozhl. Chir., 2017, roč. 96, č. 8, s. 346-352.
Category: Original articles

Overview

Introduction:
Breast cancer is the most common malignant disease in women and represents a worldwide problem. Up-to-date diagnostics methods, mammography screening and complex treatments have resulted in a substantial reduction of mortality rates. However, the incidence of the disease keeps growing constantly, although in a moderate way. The struggle against this disease has several levels, such as prevention, primary tumour therapy as well as the management of recurrent or generalized disease. Therefore, it is very significant to evaluate the prognosis on the basis of biological characteristics of the tumour and to determine the right individual therapy in each patient. Aim of the study: Our aim was to determine a group of patients with malignant breast disease based on biological characteristics of the tumour who can be treated without axillary exenteration even with a metastasis in the sentinel lymph node, thereby reducing the morbidity associated with this surgery, without worsening the prognosis.

Method:
The research project lasted from June 2012 to June 2015. It was a prospective randomized study where the main investigated group consisted of women with primarily surgically treated mammary cancer undergoing sentinel lymph node biopsy (SNB) during their surgery. These patients were divided into three groups: group 1 – positive SNB without axillary exenteration (axillary dissection – AD); group 2 – positive SNB with AD; and group 3 – negative SNB. Group 4 consisted of patients with primarily performed AD. We investigated statistically significant prognostic factors of metastatic lymph nodes and early disease progression. The results were statistically processed and differences between individual groups were evaluated, determining prognostically usable biological characteristics of the tumour in connection with metastases in lymph nodes and progression-free survival.

Results:
The study included 214 patients with breast cancer. No metastases of axillary lymph nodes were found in 136 patients (64%); on the other hand, 78 patients (36%) had positive axillary lymph nodes and included: 28 (13%) patients with a micrometastasis in the sentinel lymph node; 38 (17%) patients with 1−3 positive lymph nodes; 8 (4%) patients with 4−9 positive lymph nodes; and 4 (2%) patients had more than 10 metastatic lymph nodes. A statistically significant difference with respect to metastatic lymph node involvement was found for the tumour size, expression of oestrogen receptors, proliferative activity and grading.

Conclusion:
The following prognostic factors of metastatic lymph nodes and early disease progression were shown to be statistically significant: tumour size over 2 cm, negative expression of oestrogen receptors, tumours with moderate and high proliferative activity, and tumour grades G2 and G3. In the course of the three years of this study, no regional recurrence was found in axillary lymph nodes in any patient, and therefore, it clearly follows that the completion of axillary exenteration can be omitted in the case of tumour sizes below 2 cm, present expression of oestrogen receptors, low proliferative activity and grade 1 even if one or two positive sentinel lymph nodes are present, provided that adjuvant radiation therapy can be used. Also, axillary exenteration is not needed if a micrometastasis or isolated tumour cells are found in the sentinel lymph node.

Key words:
breast cancer – sentinel lymph node biopsy – axillary exenteration – prognostic factors


Sources

1. Becker HD, Hohenberger W, Junginger T, et al. Chirurgická onkologie. Praha, Grada Publishing 2005:21−7:115−65.

2. Coufal O, Fait V a kol. Chirurgická léčba karcinomu prsu. Praha, Grada Publishing 2011.

3. Galimberti V, Botteri E, Chifu C, et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat 2012;131:819−25.

4. Bolondi M, Farinetti A. Axillary lymph node dissection in patients with micrometastasis in sentinel lymph node: new predilections. Minerva Chir 2011;66:385−95.

5. Zoras O, Ziogas D, Roukos DH. Omitting axilla lymphadenectomy even by positive sentinel lymph node: a change in breast cancer treatment practice. Womens Health (Lond Engl) 2011;7:417−8.

6. Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 2010;17 Suppl 3:343−51.

7. Meretoja TJ, Vironen JH, Heikkilä PS, et al. Outcome of selected breast cancer patients with micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node dissection. J Surg Oncol 2010;102:215−9.

8. Maaike de Boer MD, Carolien HM, van Deurzen MD, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009;361:653−63.

9. Maaskant-Braat AJ, van de Poll-Franse LV, Voogd AC, et al. Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Res Treat 2011;127:195−203.

10. Gloyeske NC. Goreal W, O´Neil M, et al. Outcomes of breast cancer patients with micrometastases and isolated tumor cells in sentinel lymph nodes. In Vivo Nov-Dec 2011;25:997−1001.

11. Ozao-Choy J, Giuliano AE. Prognostic significance of micrometastasis and isolated tumor cells in the sentinel lymph node. Breast Cancer Res Treat 2011;127:205−6.

12. Vrána D, Gatěk J, Cwiertka K, et al. Další postupný ústup od axilární disekce u časného karcinomu prsu. Klin Onkol 2014;27:143.

13. Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat 2011;129:675−89.

14. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946−53.

15. Gatzemeier W, Mann GB. Which sentinel lymph-node positive breast cancer patient needs an axillary lymph-node dissection ACOSOG Z0011 results and beyond. Breast 2013;22:211−6.

16. EORTC study shows radiotherapy and surgery provide excellent regional control for breast cancer patients. Available from: http://www.eortc.org/news/eortc-study-shows-radiotherapy-and-surgery-provide-excellent-regional-control-breast-cancer-pat.

17. Galimberti V, Cole BF, Zurrida S, et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297−305.

18. Krsička P, Coufal O, Zapletal O. Pozitivní sentinelová uzlina u karcinomu prsu – kdy a proč doplňovat axilární disekci? Rozhl Chir 2013;92:684−9.

19. Latosinsky S, Berrang TS, Cutter CS, et al. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Can J Surg 2012;55:66−9.

20. Kotoč J, Kotočová K, Gatěk J, et al. Mikrometastáza v sentinelové uzlině – nutnost disekce axilárních uzlin? Prakt Lék 2009;89:587−90.

21. Abreu EB, Martinez P, Betancourt L, et al. Treatment plan for breast cancer with sentinel node metastasis. Ecancermedicalscience 2014;8:383.

22. Tjan-Heijnen V, Pepels M, Boer M, et al. Impact of omission of completion axillaries lymph node dissection or axillaries radiotherapy in breast cancer patients with micro metastasis or isolated tumor cells in the sentinel lymph node: results from the MIRROR study. J Clin Oncol 2009;27:18.

23. Rutledge H, Davis J, Chiu R, et al. Sentinel node micrometastasis in breast carcinoma may not be an indication for complete axillary dissection. Mod Pathol 2005;18:762−8.

24. van Deurzen CH, van Hillegersberg R, Hobbelink MG, et al. Predictive value of tumor load in breast cancer sentinel lymf nodes for second echelon lymph node metastases. Cell Oncol 2007;29:497−505.

25. Boler DE, Uras C, Ince U, et al. Factors predicting the non-sentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases. Breast 2012;21:518−23.

26. Pernas S, Gil M, Benítez A, et al. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence. Ann Surg Oncol 2010;17:772–7.

27. Ozmen V, Karanlik H, Cabioglu N, et al. Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat 2006;95:1−6.

28. Dengel LT, Van Zee KJ, King TA, et al. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol 2014;21:22−7.

29. Harlow SP, Weaver DL. Sentinel lymph node dissection for breast cancer: Indications and outcomes. Available from: http://www.uptodate.com/contents/sentinel-lymph-node-dissection-for-breast-cancer-indications-and-outcomes/.

Labels
Surgery Orthopaedics Trauma surgery
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#